Novartis’s renaissance gets off to a false start
Leqvio’s launch remains sluggish and tislelizumab looks even more like a dead end in the US.
The Wegovy wait continues
Novo Nordisk delays the full US launch of its obesity drug again, as Lilly breathes down its neck.
Investors bite the big pharma hands that feed them
Spending heavily on buybacks and dividends does not mean sector-leading share price performance, Evaluate Vantage finds.
Covid drives a record jump in research spending for big pharma
A second year of pandemic investments helped big pharma’s combined R&D bill surge above $100bn for the first time.
Glaxo gets a Shingrix boost
But pressure is on the shingles vaccine as the consumer spin-off approaches.
Healthineers scores big in the third quarter
Diagnostics companies enjoy notable uplift in sales; elsewhere, spinouts could shape the future.
